3728 Jinke Rd, Building 1, West Wing, Shanghai, China
info@tyligand.com
Chinese Version（中文版）
Home
About
Company Profile
Leadership Team
Investors
Research
Focusing Fields
Platforms
Pipelines
Partnership
News
Corporate News
Career
Talent Philosophies
Join Tyligand
Contact
2024
Enter Part of Title
Filter
Clear
Display #
5
10
15
20
25
30
50
100
All
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting
